Syndax Pharmaceuticals (SNDX) EBT: 2015-2020
Historic EBT for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Dec 2020 value amounting to -$19.9 million.
- Syndax Pharmaceuticals' EBT fell 39.81% to -$19.9 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$71.4 million, marking a year-over-year decrease of 24.13%. This contributed to the annual value of -$318.5 million for FY2024, which is 52.40% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported EBT of -$19.9 million as of Q4 2020, which was down 0.04% from -$19.9 million recorded in Q3 2020.
- Syndax Pharmaceuticals' EBT's 5-year high stood at -$8.4 million during Q2 2016, with a 5-year trough of -$19.9 million in Q4 2020.
- For the 3-year period, Syndax Pharmaceuticals' EBT averaged around -$17.1 million, with its median value being -$17.2 million (2018).
- As far as peak fluctuations go, Syndax Pharmaceuticals' EBT tumbled by 145.93% in 2016, and later increased by 26.52% in 2019.
- Over the past 5 years, Syndax Pharmaceuticals' EBT (Quarterly) stood at -$10.9 million in 2016, then crashed by 74.99% to -$19.0 million in 2017, then decreased by 1.61% to -$19.3 million in 2018, then grew by 26.52% to -$14.2 million in 2019, then crashed by 39.81% to -$19.9 million in 2020.
- Its last three reported values are -$19.9 million in Q4 2020, -$19.9 million for Q3 2020, and -$16.6 million during Q2 2020.